Phathom Pharmaceuticals, INC Form 4 insider transactions

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, reports acquisition of restricted stock units and disposal of common stock.

Director Frank Karbe reports acquisition and disposition of Phathom Pharmaceuticals (PHAT) common stock.

Director James Topper reports acquisition of stock and option awards from Phathom Pharmaceuticals.

Director Asit Parikh reports acquisition of 10,500 shares of common stock and 17,500 stock options in Phathom Pharmaceuticals.

Director Michael F. Cola reported the acquisition of restricted stock units and stock options in Phathom Pharmaceuticals, as well as the disposal of common stock.

Director Heidi Fields reports receiving stock and option grants from Phathom Pharmaceuticals on May 23, 2024.

Director Frank Karbe reports acquisition of stock and stock options in Phathom Pharmaceuticals.

Director Mark Stenhouse reports acquisition of restricted stock units and stock options in Phathom Pharmaceuticals.

Director David A. Socks reported the acquisition of stock and option grants in Phathom Pharmaceuticals, according to a Form 4 filing.

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, sold 3,435 shares of common stock on April 8, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Phathom Pharmaceuticals' CEO, Terrie Curran, sold 16,851 shares of common stock at an average price of $9.11 on March 22, 2024.